TC Biopharm (Holdings) Plc (TCBP)

Market Cap	3.93M
Revenue (ttm)	2.41M
Net Income (ttm)	-16.56M
Shares Out	794.95K
EPS (ttm)	-0.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,276
Open	5.00
Previous Close	4.97
Day's Range	4.91 - 5.04
52-Week Range	2.81 - 175.00
Beta	n/a
Analysts	Buy
Price Target	255.00 (+5,069.27%)
Earnings Date	n/a

About TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 11, 2022
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: TCBP

Financial Performance

In 2021, TCBP's revenue was 1.98 million, a change of 0.00% compared to the previous year's 1.98 million. Losses were -13.58 million, 148.7% more than in 2020.

Financial numbers in GBP

Analyst Forecast

According to 7 analysts, the average rating for TCBP stock is "Buy." The 12-month stock price forecast is $255.0, which is an increase of 5,069.27% from the latest price.

Price Target

$255.0

(5,069.27% upside)

Analyst Consensus: Buy